respiratory

News

AZ boosted by COPD triple inhaler results

AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease (COPD) after a late-stage trial success.

News

AZ's cancer and respiratory drugs approved in Japan

Two AstraZeneca (AZ) drugs have been approved in Japan – its cancer drug Lynparza and its respiratory drug Fasenra.

News

Rumours of $1.65bn GSK bid for respiratory partners Vectura

GlaxoSmithKline could be poised to acquire its respiratory partner, UK biotech Vectura, for $1.65bn.

Views & Analysis

Inhalation technology: the future of effective respiratory t...

Simon Moore discusses non-clinical development channels: technical strategies, formulations and devices.

News

AZ's asthma drug Fasenra approved in EU

A further 3,400 children are eligible for treatment with Orkambi

News

Sunovion's COPD nebuliser approved in US

Device aims to help patients get a full dose of medication

AZ boosted by COPD triple inhaler results

AZ's cancer and respiratory drugs approved in Japan

Rumours of $1.65bn GSK bid for respiratory partners Vectura

Inhalation technology: the future of effective respiratory t...

AZ's asthma drug Fasenra approved in EU

Sunovion's COPD nebuliser approved in US

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

respiratory

Editor's Picks